Labcorp Finalizes Acquisition of Providence's Outreach Laboratory Business in Northern California and Orange County

Agreement includes ambulatory lab draw stations and an ambulatory laboratory facility;
aims to provide broader access to comprehensive testing and 
laboratory services for patients and physicians
 

BURLINGTON, N.C., Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Providence’s laboratory business operated by its California medical groups, including ambulatory lab draw stations and an ambulatory laboratory facility and other equipment.

The acquisition builds upon Labcorp’s existing presence in the region and its 20-year relationship with Providence to provide testing and laboratory services. Upon full integration, providers and patients in Northern California and Orange County who formerly received lab services from Providence will have access to Labcorp’s leading clinical laboratory services, robust data and digital tools.

“We are committed to continuing the longstanding tradition of high-quality laboratory and healthcare services that patients in Northern California and Orange County have come to expect and deserve,” said Rajat Mehta, Senior Vice President of Labcorp’s West Division. “We plan to use our expertise and capabilities to improve the efficiency and access of laboratory testing services for physicians and patients across California.”

Labcorp has also opened new ambulatory draw stations in Fortuna, Santa Rosa, Fullerton and Santa Monica to provide patients and physicians with increased access to its comprehensive test menu, lab medicine expertise and support capabilities. Patients can visit Labcorp’s lab locator for hours of operation and online appointment scheduling for the nearest patient service center.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

SOURCE Labcorp

Media: Kimbrel Arculeo, 336-436-8263, [email protected]; or Investors: Christin O'Donnell, 336-436-5076, [email protected]